Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is AbbVie a Bad News Buy?

TheMotleyFool

0 0

The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.

Source Fool.com

Like: 0

ABBV

Share